



**Table S1.** Demographics of PDAC patients with isolated pulmonary metastasis (Synchronous vs. Metachronous).

| <b>Variables</b>       | <b>Synchronous(n=26)</b> | <b>Metachronous(n=57)</b> | <b>P-value</b> |
|------------------------|--------------------------|---------------------------|----------------|
| Age (Years) > 65       | 16 (61.5%)               | 27 (47.4%)                | 0.231          |
| Sex (Male)             | 14 (53.8%)               | 25 (43.9%)                | 0.398          |
| Tumor location (Head)  | 11 (42.3%)               | 31 (54.4%)                | 0.307          |
| Tumor size (mm) > 28   | 12 (46.2%)               | 18 (31.6%)                | 0.200          |
| Clinical N stage (cN+) | 8 (30.8%)                | 8 (14.0%)                 | 0.073          |
| CEA (ng/ml) > 5        | 7 (26.9%)                | 12 (21.1%)                | 0.555          |
| CA 19-9 (U/ml) > 37    | 24 (92.3%)               | 31 (24.4%)                | 0.001          |

**Table S2.** Demographics of PDAC patients with isolated pulmonary metastasis (Single vs. Oligometastases vs. Multiple).

| <b>Variables</b>       | <b>Single(n=23)</b> | <b>Oligo(n=29)</b> | <b>Multiple(n=31)</b> | <b>P-value</b> |
|------------------------|---------------------|--------------------|-----------------------|----------------|
| Age (Years) > 65       | 13 (56.5%)          | 17 (58.6%)         | 13 (41.9%)            | 0.376          |
| Sex (Male)             | 13 (56.5%)          | 9 (31.0%)          | 17 (54.8%)            | 0.102          |
| Tumor location (Head)  | 11 (47.8%)          | 16 (55.2%)         | 15 (48.4%)            | 0.829          |
| Tumor size (mm) > 28   | 6 (26.1%)           | 10 (34.5%)         | 14 (45.2%)            | 0.187          |
| Clinical N stage (cN+) | 4 (17.4%)           | 4 (13.8%)          | 8 (25.8%)             | 0.481          |
| CEA (ng/ml) > 5        | 5 (21.7%)           | 8 (27.6%)          | 6 (19.4%)             | 0.741          |
| CA 19-9 (U/ml) > 37    | 11 (47.8%)          | 22 (75.9%)         | 22 (71.0%)            | 0.082          |



**Figure S1.** (a). Recurrence patterns after pancreatectomy in PDAC patients with metachronous metastasis. (b). Recurrence free survival in PDAC patients with metachronous metastasis confined to a specific site. Median recurrence free survival: Lung (18 months), Local (12 months), Peritoneal seeding (11 months), Liver (5 months).